Xenon Pharmaceuticals Inc has a consensus price target of $52.88, established from looking at the 41 latest analyst ratings. The last 3 analyst ratings were released from Needham, Cantor Fitzgerald, and RBC Capital on April 12, 2024, April 10, 2024, and March 1, 2024. With an average price target of $60.67 between Needham, Cantor Fitzgerald, and RBC Capital, there's an implied 53.59% upside for Xenon Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
04/12/2024 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 56.96% | Needham | Serge Belanger | → $62 | Reiterates | Buy → Buy | Get Alert |
04/10/2024 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 64.56% | Cantor Fitzgerald | Josh Schimmer | → $65 | Reiterates | Overweight → Overweight | Get Alert |
03/01/2024 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 39.24% | RBC Capital | Brian Abrahams | $56 → $55 | Maintains | Outperform | Get Alert |
03/01/2024 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 29.11% | Wedbush | Laura Chico | $46 → $51 | Maintains | Outperform | Get Alert |
03/01/2024 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 56.96% | Needham | Serge Belanger | $50 → $62 | Maintains | Buy | Get Alert |
01/04/2024 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 56.96% | Citigroup | David Hoang | → $62 | Initiates | → Buy | Get Alert |
01/02/2024 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 41.77% | B of A Securities | Jason Gerberry | $52 → $56 | Maintains | Buy | Get Alert |
12/18/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 56.96% | Stifel | Stephen Willey | $53 → $62 | Maintains | Buy | Get Alert |
12/08/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 59.49% | Baird | Brian Skorney | → $63 | Initiates | → Outperform | Get Alert |
11/28/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 41.77% | RBC Capital | Brian Abrahams | $51 → $56 | Maintains | Outperform | Get Alert |
11/09/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 16.46% | Wedbush | Laura Chico | $47 → $46 | Maintains | Outperform | Get Alert |
10/24/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | — | Cantor Fitzgerald | Josh Schimmer | — | Assumes | → Overweight | Get Alert |
09/22/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 29.11% | RBC Capital | Brian Abrahams | → $51 | Reiterates | Outperform → Outperform | Get Alert |
08/22/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 46.84% | Cantor Fitzgerald | Charles Duncan | → $58 | Reiterates | Overweight → Overweight | Get Alert |
08/10/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 18.99% | Wedbush | Laura Chico | → $47 | Reiterates | Outperform → Outperform | Get Alert |
08/10/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 26.58% | Needham | Serge Belanger | → $50 | Reiterates | Buy → Buy | Get Alert |
07/17/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 29.11% | RBC Capital | Brian Abrahams | → $51 | Reiterates | Outperform → Outperform | Get Alert |
06/21/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 46.84% | Cantor Fitzgerald | Charles Duncan | → $58 | Reiterates | Overweight → Overweight | Get Alert |
06/15/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $39.50 | 24.05% | Guggenheim | Yatin Suneja | → $49 | Reiterates | Buy → Buy | Get Alert |
The latest price target for Xenon Pharmaceuticals (NASDAQ: XENE) was reported by Needham on April 12, 2024. The analyst firm set a price target for $62.00 expecting XENE to rise to within 12 months (a possible 56.96% upside). 20 analyst firms have reported ratings in the last year.
The latest analyst rating for Xenon Pharmaceuticals (NASDAQ: XENE) was provided by Needham, and Xenon Pharmaceuticals reiterated their buy rating.
There is no last upgrade for Xenon Pharmaceuticals.
There is no last downgrade for Xenon Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xenon Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xenon Pharmaceuticals was filed on April 12, 2024 so you should expect the next rating to be made available sometime around April 12, 2025.
While ratings are subjective and will change, the latest Xenon Pharmaceuticals (XENE) rating was a reiterated with a price target of $0.00 to $62.00. The current price Xenon Pharmaceuticals (XENE) is trading at is $39.50, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.